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The role of cyclic ADP-ribose (cADPR) as a second messenger and modulator of the 
mTOR pathway downstream of dopamine (DA) receptors and/or CD38 was 
re-examined in the mouse. ADP-ribosyl activity was low in the membranes of neonates 
but was stimulated by DA via both D1- and D2-like receptors. ADP-ribosyl cyclase 
activity increased significantly during development in association with increased 
expression of CD38. The cADPR binding proteins, FKBP12 and FKBP12.6, were 
expressed in the adult mouse striatum. The ratio of phosphorylated to 
non-phosphorylated S6 kinase (S6K) in whole mouse striatum homogenates decreased 
after incubation of adult mouse striatum with extracellular cADPR for 5 minutes. This 
effect of cADPR was much weaker in MPTP-treated Parkinson’s disease model mice. 
The inhibitory effects of cADPR and rapamycin were identical. These data suggest that 
cADPR is an endogenous inhibitor of the mTOR signaling pathway downstream of DA 
receptors in the mouse striatum and that cADPR plays a certain role in the brain in 
psychiatric and neurodegenerative diseases.  




Dr. Toshiharu Nagatsu and the first author (H.H.) examined monoamine 
oxidase A and B (Nagatsu et al., 1981; Nakano et al., 1986a and b) and serotonin 
(Suzuki et al., 1983; Furuya et al., 10985) in rodent neuroblastoma clones, with 
permission from Dr. Nirenberg, National Institutes of Health, U.S.A. Dr. Nagatsu 
suggested that Higashida focused on amines and Parkinson’s disease. However, 
Higashida’s and his fellow researchers’ main interests at that time were on bradykinin, 
muscarinic acetylcholine receptors and their coupling to phospholipase C (Yano et al., 
1986; Higashida et al., 1986; Fukuda et al., 1988) and later to ADP-ribosyl cyclase 
(Higashida et al., 2001; Jin et al., 2007). Higashida and his colleagues concentrated on 
intracellular signaling leading to the modulation of membrane excitation and 
acetylcholine release (Hoshi et al., 2003). However, when Higashida and others used 
neuroblastoma cells as a tool to overexpress dopamine (DA) receptors (Higashida et al., 
2013), they realized that there is little information on the coupling of DA receptors and 
ADP-ribosyl cyclase to a potential second messenger, cyclic ADP-ribose (cADPR), 
which is downstream of DA receptors.    
DA receptors are involved in many physiological functions, such as 
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extrapyramidal motor control, short-term memory, attention, and reward (Greengard, 
2001; Iversen and Iversen, 2007; Nagatsu, 2007; Nagatsu and Nagatsu, 2016). In 
contrast, abnormal activity of the DA system has been implicated in neurological and 
psychiatric disorders, such asParkinson’s disease (PD), schizophrenia, bipolar disorder, 
and attention deficit hyperactivity disorder (Nagatsu, 2007). Therefore, the study of DA 
receptor-mediated intracellular signal transduction has been a primary approach to 
understanding the physiological functions or PD-related aspects of DA-related cellular 
responses (Baker et al., 2015).  
From the viewpoint of signal transduction, D1- and D2-class DA receptor 
subtypes positively and negatively regulate adenylyl cyclase, respectively (Greengard, 
2001; Missale et al., 1998). Stimulation of D2 receptors can increase intracellular Ca2+ 
concentrations by mobilizing Ca2+ from inositol-1,4,5-trisphosphate-sensitive stores 
(Frégeau et al., 2013). Increases in intracellular free calcium concentration ([Ca2+]i) 
seem to be mediated by the interaction of DA receptors with neuronal calcium sensor-1 
or calcyon (Bergson et al., 2003). However, we recently reported a new pathway that is 
dependent on cyclic ADP-ribose (cADPR) (Lee, 2012) downstream of DA receptors 
and CD38 with ADP-ribosyl cyclase activity in rodents (Higashida et al., 2013). 
 cADPR is a co-factor of Ca2+-induced Ca2+ release that activates Ca2+ release 
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from ryanodine receptors in microsomes (Lee, 2012; Hua et al., 1994; Okamoto et al., 
2014; Higashida et al., 2001). cADPR is synthesized from β-NAD+ by both cytosolic 
and membrane-bound forms of ADP-ribosyl cyclase and/or CD38 (Higashida et al., 
2007; Kim, 2014). ADP-ribosyl cyclase activity increases upon stimulation of various 
receptors; some of this activity is observed in only neonates, not adult tissues of the 
same organs (Higashida et al., 2007). 
 The mammalian target of rapamycin (mTOR) pathway has emerged as a 
regulator of neuroplasticity in the central nervous system (CNS; Bockaert and Marin, 
2015; Tramutola et al., 2016). mTOR is a Ser/Thr protein kinase complex that responds 
to multiple extracellular stimuli, such as nutrients, energy, growth factors, and mitogens 
that regulate cell growth, cell survival, transcription, and protein synthesis 
(Wullschleger et al., 2006; Hoeffer and Klann, 2010; Sukhbaatar et al., 2016). 
Deregulation of the mTOR pathways occurs in pathological conditions, such as cancer 
and neurodegenerative diseases characterized by long-term alterations in protein 
expression (Wullschleger et al., 2006). Administration of L-DOPA in a mouse model of 
Parkinson’s disease leads to DA D1 receptor-mediated activation of mTOR complex 1 
(mTORC1), which has been implicated in several forms of synaptic plasticity (Hoeffer 
and Klann, 2010). This response occurs selectively in GABAergic medium spiny 
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neurons that project directly from the striatum to the output structures of the basal 
ganglia. The L-DOPA-mediated activation of mTORC1 persists in mice that develop 
dyskinesia (Santini et al., 2009). Moreover, the mTORC1 inhibitor rapamycin prevents 
the development of dyskinesia without affecting the therapeutic efficacy of L-DOPA. 
Thus, the mTORC1 signaling cascade represents a promising target for therapeutics to 
treat the negative motor symptoms induced by anti-parkinsonian therapies (Santini et al., 
2009; Lipton et al., 2014; Buszczak et al., 2014; Roohi and Hojjat-Farsangi, 2016). 
 mTORC1 is sensitive to rapamycin via competition between a mTOR 
regulatory protein (Raptor) and FKBP12-rapamycin for binding to the FRB domain 
(Buszczak et al., 2014; Thomson et al., 2009; Haeffer et al., 2008; Hausch, 2015). 
mTOR signaling is suppressed by rapamycin and FK506 in the brain. Removal of 
neuronal FKBP resulted in enhanced mTORC1 formation and increased 
phosphorylation of S6 kinase 1 (S6K1; Thompson et al., 2009). Thus, FKBP12 appears 
to repress mTORC1 activity. Another member of the FKBP family, FKBP12.6, can 
mediate the immunosuppressive effects of FK506 and act as a receptor for cADPR 
(Hoeffer et al., 2008; Hausch, 2015; Noguchi et al., 2007). The roles of FK12.6 and the 
FKBP12.6-cADPR complex were in part demonstrated by immunoblotting analysis of 
the striatum of control and MPTP-treated mice (Higashida et al., 2013). Here, we 
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re-examined the mouse striatum to support our hypothesis that cADPR functions as an 
endogenous modulator of the mTOR pathway downstream of DA receptors. 
 
Materials and Methods 
Membrane preparation  
Crude membrane fractions were prepared as described previously from male ICR mice 
for the ADP-ribosyl cyclase assays (Higashida et al., 1997).  
 
Fluorometric measurement of ADP-ribosyl cyclase  
ADP-ribosyl cyclase activity was determined fluorometrically using a technique based 
on measuring the conversion of β-NGD+ into the fluorescent product cyclic GDP-ribose 
(cGDP-ribose), as described previously (Higashida et al., 1997; Higashida et al., 2002; 
Greff and Lee, 2002). The samples were then excited at 300 nm, and fluorescence 
emission was monitored continuously at 410 nm with a spectrofluorophotometer 
(RF-6000; Shimadzu, Kyoto, Japan). 
 
Incubation of the striatum 
Striata were isolated from the brains of 9-week-old male ICR mice or mice treated with 
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an intraperitoneal injection of MPTP (20 mg/kg, 4 times/day at 2-hour intervals; 
Higashida et al., 2013). The striata were kept in medium (pH 7.3) containing 124 mM 
NaCl, 5 mM KCl, 1.24 mM KH2PO4, 2 mM CaCl2, 25.9 mM NaHCO3, and 10 mM 
glucose for 1 hour at room temperature and bubbled with a mixture of 95% O2/5% CO2. 
The tissue was further incubated with or without 100 μM cADPR, 100 nM DA or 100 
nM DA + 100 μM cADPR for 5 minutes at 32°C. Certain tissues were preincubated 
with 8-Bromo-cADPR (Sigma-Aldrich Sweden AB, Stockholm, Sweden) for 1 hour.  
Then, tissues were immediately homogenized in lysis buffer containing 0.1% Triton 
X-100, 10% glycerol, 1.5 mM EDTA, 0.5 mM Na3VO4, 10 mM NaF, and 1× protease 
inhibitor cocktail (Roche, Mannheim, Germany). Protein concentration was determined 
by BCA assay (Thermo Fisher Scientific, Inc., Waltham, MA).  
 
Western blotting and PCR  
Aliquots of 30 μg of protein were subjected to SDS-polyacrylamide gel electrophoresis 
(SDS-PAGE). The membranes were incubated with anti-phospho-p70 S6K (Thr389) 
and anti-p70 S6K antibodies (both from Cell Signaling Technology, Beverly, MA) in 
blocking buffer overnight at 4°C and then for 3 hours at room temperature (both 
antibodies were diluted 1:500). The membranes were then processed and visualized as 
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described previously (Higashida et al., 2013). RT-PCR analysis was performed as 
described previously (Higashida et al., 2013). 
  
Statistics 
All results are expressed as the mean ± SEM. One- or two-tailed Student’s t-tests and 
one-way ANOVA combined with the Bonferroni test were used to analyze data with 
unequal variance between groups. Two-way ANOVA was used to assess Treatment x 




ADP-ribosyl cyclase activity in the mouse striatum 
ADP-ribosyl cyclase activity was measured in crude membrane fractions isolated from 
the striatum of mice at various ages. Basal ADP-ribosyl cyclase activity was very low, 
i.e., approximately 0.1 to 1.6 pmol cGDPR formed/min/mg protein in preparations from 
1–3 day prenatal and 1–5 day postnatal mice, respectively. ADP-ribosyl cyclase activity 
increased sharply with age after postnatal day 5 (Figure 1; P < 0.001, F(12,65) = 59.68, R2 
= 0.9168, one-way ANOVA), reaching a very high level by 12 days of age (21.6 ± 3.7 
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pmol cGDPR formed/min/mg protein, n = 12), which was 40-fold higher than the basal 
activity at birth (P < 0.001, Bonferroni’s post-hoc test).  
 
Sensitivity to dopamine  
ADP-ribosyl cyclase activity was analyzed in striatal membranes from mouse neonates 
at birth (day 0) and postnatal days 1–11 in the presence of 100 nM DA in the reaction 
mixture. From neonatal day 1 to 4, the increase ranged from 130% to 310%. However, 
after 12 days, DA-induced activation dropped to less than 105 ± 10% and remained at 
this level until the adult stage. 
 The concentration–response relationship to DA was examined (Figure 2). The 
increases induced by DA (with or without 10 nM GTP), SKF38393 (SKF, a D1-like 
agonist), and bromocriptine mesylate (BC, a D2-like agonist) were dose-dependent. 
Two-way ANOVA demonstrated significant Treatment (±GTP) x Concentration (DA) 
interaction (P = 0.0261, F(6,126) = 2,49; Figure 2A). One-way ANOVA demonstrated 
significant difference in experiments with SKF (P < 0.001, F(5,54) = 12.88, R2 = 0.5439) 
and BC treatment (P < 0.001, F(4,45) = 17.00, R2 = 0.6018; Figure 2B). The maximum 
effects of these three agents were obtained at different concentrations between 1 and 
100 nM. The maximum response of 202.8 ± 21.4% of the control (n = 10, P < 0.01, 
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Bonferroni’s post-hoc test) was obtained with 100 nM DA. Significant increases to 
183.0 ± 12.2% (n = 10, P < 0.01, Bonferroni’s post-hoc test) and 157.9 ± 5.3% (n = 10, 
P < 0.01) of the control were obtained with 10 nM SKF and 1 nM BC, respectively.  
 
CD38 expression 
We examined whether the increased ADP-ribosyl cyclase activity is due to an increase 
in CD38 expression. While a band of approximately 42 kDa was detected in the 1-week 
striatum, CD38 protein abundance was significantly increased after 2 weeks and in adult 
mice (10 weeks old), as shown by Western blotting (Figure 3). 
 RT-qPCR analysis indicated that CD38 mRNA expression levels increased 
significantly with age (data not shown). CD38 mRNA expression relative to β-actin 
expression was approximately 29.8-fold higher in adult mice (2 weeks old) than in mice 
at postnatal day 1 (P < 0.001, two-tailed t test).  
 
Expression of FKBP in the mouse brain  
Next, the expression of FKBP12 and the close homolog FKBP12.6 was examined in 
various brain regions of 9-week-old male mice by RT-PCR. FKBP12 was ubiquitously 
detected in four regions (cerebrum, cerebellum, hypothalamus and striatum) and the 
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pituitary, with no significant differences among them, based on the relative expression 
normalized to β-actin (Higashida et al., 2013). In contrast, the FKBP12.6 expression 
level was lower in the striatum than in the cerebrum, cerebellum, and hypothalamus in 
9-week-old male mice (Figure 4), suggesting region-specific expression. The result 
provides minimal necessary evidence for a functional role of cADPR/FKBP12 or 
cADPR/FKBP12.6 binding complexes in mTOR signaling in the striatum.  
 
Effects of cADPR on S6 kinase 
The mammalian target of rapamycin (mTOR) activates S6 kinase (S6K), which is 
responsible for phosphorylation of the ribosomal protein S6 (S6), a component of the 
40S ribosomal subunit (Bockaert and Marin, 2015; Busxczak et al., 2014). cADPR (100 
µM) was added to the incubation medium for 9-week-old mouse striatum samples for 5 
minutes with or without DA receptor stimulation by 100 nM DA (Figure 5A and B). DA 
itself did not cause significant inhibition of S6K phosphorylation, being calculated as 
the percentage change between 0 and 5 minutes (P-S6K/S6K at 5 minutes divided by 
P-S6K/S6K at 0 minutes): 1.28 ± 0.16 (n = 22; Table 1) in the absence and 1.42 ± 0.25 (n 
= 5) in the presence of DA. This result well accords with the report in the nucleus 
accumbens by D1 stimulation (Sutton and Caron, 2015).   
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One-way ANOVA demonstrated no significant difference between treatments 
without (Figure 5A; P > 0.05, F(2,43) = 2.595, R2 = 0.1077) or with DA receptor 
stimulation (Figure 5B; P = 0.2741, F(2,45) = 1.332, R2 = 0.0558). In whole-cell 
homogenates, S6K phosphorylation at Thr389 significantly decreased in both the 
presence and absence of DA (n = 16 mice each, P < 0.01, Bonferroni’s post-hoc test)). 
This cADPR-induced decrease in S6K phosphorylation was reversed by prior 
administration of 100 µM 8-bromo-cADPR, a cADPR antagonist (n = 14, P < 0.02, 
Bonferroni’s post-hoc test)). The total amount of S6K was unaffected by cADPR 
treatment with or without DA or 8-bromo-cADPR. 
 The effects of cADPR were compared with those of rapamycin. Rapamycin 
was added to the incubation medium 1 h prior to experiments at a final concentration of 
100 µM (Table 1). One-way ANOVA demonstrated significant effects of antagonist 
treatment (P < 0.0001, F(2,53) = 4152, R2 = 0.9937). Significant inhibition (44% of that 
without rapamycin) of S6K phosphorylation at Thr389 in whole-cell homogenates was 
obtained with rapamycin (n = 16, P < 0.001, Bonferroni’s post-hoc test), which was 
equivalent to the effect of cADPR (59%). In addition, we determined that the decreased 
kinase activity is independent of protein kinase C but slightly influenced by protein 




The results of the present study, together with our previous report (Higashida et al., 
2013), indicate that ADP-ribosyl cyclase activity in the mouse striatum is enhanced by 
DA stimulation during the neonatal period (up to about postnatal day 11) but not in 
adults. These observations agree with those of our previous study of angiotensin II 
receptors in ventral cardiac cells (Higashida et al., 2000), in which activation by 
angiotensin was observed on neonatal day 4. Similar activation of ADP-ribosyl cyclase 
by Gs-coupled D1-like receptors and Gi-coupled D2-like receptors was obtained in the 
mouse striatum. However, this is not unexpected, because we have shown that 
Gi-coupled mGluR3 (type IIa) stimulates ADP-ribosyl cyclase, while Gs-coupled 
mGluR1 and mGluR5 (type Ia) also stimulate ADP-ribosyl cyclase (Higashida et al., 
2003). Therefore, DA may play a certain role in the early development through cADPR. 
In the adult period, ADP-ribosyl cyclase activity was > 40-fold higher in the 
mouse (current results) and > 100-fold higher in the rat (Higashida et al., 2013). The 
mRNA and protein levels of CD38 were significantly increased after postnatal days 5 – 
10. It is possible that cADPR is abundant as an endogenous intermediate product of 
ADP-ribosyl cyclase and/or CD38 in the adult mouse striatum. 
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cADPR significantly inhibited the phosphorylation of S6K, the translational 
regulatory kinase and downstream target of mTORC1 (Bockaert and Marin, 2015; 
Wullschleger et al., 2006; Hoeffer et al., 2010). This cADPR-induced inhibition of S6K 
phosphorylation was reproduced by rapamycin, a well-known inhibitor of mTOR 
signaling through FKBP (Lipton and Sahin, 2014; Hoeffer et al., 2008). This result 
seems to indicate that cADPR shares the well-documented rapamycin pathway 
(Bockaert and Marin, 2015; Wullschleger et al., 2006; Lipton and Sahin, 2014; 
Buszczak et al., 2014). Therefore, since exogenous cADPR and rapamycin inhibited the 
mTOR pathway, it is possible that endogenously synthesized cADPR functions to 
inhibit mTOR signaling in the intact adult striatum (Figure 6).  
Interestingly, with regard to PD, we have shown that cADPR-induced S6K 
phosphorylation was diminished in the MPTP-treated mouse brain (see also Higashida 
et al., 2013). This observation is consistent with the enhanced mTOR signaling in the 
PD model brain (Bockaert and Marin, 2015). It is hypothesized that when the mTOR 
signal is enhanced by the chronic use of L-DOPA, translation is subsequently increased, 
which may lead to involuntary movement (Santini et al., 2009; Lipton and Sahin, 2014). 
In sum, we propose that the endogenous presence of cADPR is likely a 
safeguard for maintaining or suppressing translation at a constant rate under conditions 
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of mTOR activation observed in brain dysfunction, such as that in PD (Figure 6). 
 
Conflicts of Interest 




This work was supported by grant-in-aid from by the Industry-Academia Collaborative 
R & D Programs (COI) from the Ministry of Education, Culture, Sports, Science and 







Barker RA, Drouin-Ouellet J, Parmar M (2015) Cell-based therapies for Parkinson 
disease—past insights and future potential. Nat Rev Neurol 11(9):492-503 
 
Bergson C, Levenson R, Goldman-Rakic PS, Lidow MS (2003) Dopamine 
receptor-interacting proteins: the Ca2+ connection in dopamine signaling. Trends 
Pharmacol Sci 24(9):486-492 
 
Bockaert J, Marin P (2015) mTOR in brain physiology and pathologies. Physiol Rev 
95(4):1157-1187 
 
Buszczak M, Signer RA, Morrison SJ (2014) Cellular differences in protein synthesis 
regulate tissue homeostasis. Cell 159(2):242-251 
 
Ceni C, Muller-Steffner H, Lund F, Pochon N, Schweitzer A, De Waard M, Schuber F, 
Villaz M, Moutin MJ (2003) Evidence for an intracellular ADP-ribosyl 
cyclase/NAD+-glycohydrolase in brain from CD38-deficient mice. J Biol Chem 
278(42):40670-40678 
 
De Flora A, Zocchi E, Guida L, Franco L, Bruzzone S (2004) Autocrine and paracrine 
calcium signaling by the CD38/NAD+/cyclic ADP-ribose system. Ann N Y Acad Sci 
1028:176-191 
 
Frégeau MO, Carrier M, Guillemette G (2013) Mechanism of dopamine D2 
receptor-induced Ca2+ release in PC-12 cells. Cell Signal 25(12):2871-2877  
 
Fukuda K, Higashida H, Kubo T, Maeda A, Akiba I, Bujo H, Mishina M, Numa S 
(1988) Selective coupling with K+ currents of muscarinic acetylcholine receptor 
subtypes in NG108-15 cells. Nature. 335(6188):355-358  
 
Furuya S, Sawada M, Nagatsu T, Suzuki O, Higashida H (1985) Localization of 
[3H]serotonin in neuroblastoma x glioma hybrid cells. Brain Res 361(1-2):77-90  
 18 
 
Graeff R, Lee HC (2002) A novel cycling assay for nicotinic acid-adenine dinucleotide 
phosphate with nanomolar sensitivity. Biochem J 367(Pt 1):163-168  
 
Greengard P (2001) The neurobiology of slow synaptic transmission. Science 
294(5544):1024-1030 
 
Higashida C, Islam MS, Kamimura S, Inoue T, Jin D, Zhang J, Hashii M, Liang M, 
Zhong J, Hori O, Fukunaga K, Okamoto H, Graeff R, Lee HC, Higashida H (2013) 
Dopamine-induced regulation and deregulation of the catabolism of cyclic ADP-ribose, 
an intrinsic mTOR signal inhibitor, during development in the rodent striatum. 
Messenger 2(1):33-43 
 
Higashida H, Brown DA (1986) Two polyphosphatidylinositide metabolites control two 
K+ currents in a neuronal cell. Nature 323(6086):333-335 
 
Higashida H, Egorova A, Higashida C, Zhong ZG, Yokoyama S, Noda M, Zhang JS 
(1999) Sympathetic potentiation of cyclic ADP-ribose formation in rat cardiac 
myocytes. J Biol Chem 274(47):33348-33354 
 
Higashida H, Hashii M, Yokoyama S, Hoshi N, Asai K, Kato T (2001) Cyclic 
ADP-ribose as a potential second messenger for neuronal Ca2+ signaling. J Neurochem 
76(2):321-331 
 
Higashida H, Hashii M, Yokoyama S, Hoshi N, Chen XL, Egorova A, Noda M, Zhang 
JS (2001) Cyclic ADP-ribose as a second messenger revisited from a new aspect of 
signal transduction from receptors to ADP-ribosyl cyclase. Pharmacol Ther 
90(2-3):283-296 
 
Higashida H, Hossain KZ, Takahagi H, Noda M (222) Measurement of adenylyl cyclase 




Higashida H, Salmina AB, Olovyannikova RY, Hashii M, Yokoyama S, Koizumi K, Jin 
D, Liu HX, Lopatina O, Amina S, Islam MS, Huang JJ, Noda M (2007) Cyclic 
ADP-ribose as a universal calcium signal molecule in the nervous system. Neurochem 
Int 51(2-4):192-199 
 
Higashida H, Yokoyama S, Hashii M, Taketo M, Higashida M, Takayasu T, Ohshima T, 
Takasawa S, Okamoto H, Noda M (1997) Muscarinic receptor-mediated dual regulation 
of ADP-ribosyl cyclase in NG108-15 neuronal cell membranes. J Biol Chem 
272(50):31272-31277. 
 
Higashida H, Zhang J, Hashii M, Shintaku M, Higashida C, Takeda Y (2000) 
Angiotensin II stimulates cyclic ADP-ribose formation in neonatal rat cardiac myocytes. 
Biochem J 352(Pt 1):197-202. Erratum in: Biochem J 2001 354(Pt 3):727.  
 
Higashida H, Zhang JS, Mochida S, Chen XL, Shin Y, Noda M, Hossain KZ, Hoshi N, 
Hashii M, Shigemoto R, Nakanishi S, Fukuda Y, Yokoyama S (2003) Subtype-specific 
coupling with ADP-ribosyl cyclase of metabotropic glutamate receptors in retina, 
cervical superior ganglion and NG108-15 cells. J Neurochem 85(5):1148-1158. 
 
Hoeffer CA, Klann E (2010) mTOR signaling: at the crossroads of plasticity, memory 
and disease. Trends Neurosci 33(2):67-75  
 
Hoeffer CA, Tang W, Wong H, Santillan A, Patterson RJ, Martinez LA, Tejada-Simon 
MV, Paylor R, Hamilton SL, Klann E (2008) Removal of FKBP12 enhances 
mTOR-Raptor interactions, LTP, memory, and perseverative/repetitive behavior. 
Neuron 60(5):832-845  
 
Hoshi N, Zhang JS, Omaki M, Takeuchi T, Yokoyama S, Wanaverbecq N, Langeberg 
LK, Yoneda Y, Scott JD, Brown DA, Higashida H (2003) AKAP150 signaling complex 
promotes suppression of the M-current by muscarinic agonists. Nat Neurosci 
6(6):564-571  
 
Hua SY, Tokimasa T, Takasawa S, Furuya Y, Nohmi M, Okamoto H, Kuba K (1994) 
 20 
Cyclic ADP-ribose modulates Ca2+ release channels for activation by physiological Ca2+ 
entry in bullfrog sympathetic neurons. Neuron 12(5):1073-1079  
 
Hüsing A, Schmidt M, Beckebaum S, Cicinnati VR, Koch R, Thölking G, Stella J, 
Heinzow H, Schmidt HH, Kabar I (2015) Long-term renal function in liver transplant 
recipients after conversion from calcineurin inhibitors to mTOR inhibitors. Ann 
Transplant 26;20:707-713  
 
Hausch F (2015) FKBPs and their role in neuronal signaling. Biochim Biophys Acta 
1850(10):2035-2040   
 
Iversen SD, Iversen LL (2007) Dopamine: 50 years in perspective. Trends in Neurosci 
30(5):188-193  
 
Jin D, Liu HX, Hirai H, Torashima T, Nagai T, Lopatina O, Shnayder NA, Yamada K, 
Noda M, Seike T, Fujita K, Takasawa S, Yokoyama S, Koizumi K, Shiraishi Y, Tanaka 
S, Hashii M, Yoshihara T, Higashida K, Islam MS, Yamada N, Hayashi K, Noguchi N, 
Kato I, Okamoto H, Matsushima A, Salmina A, Munesue T, Shimizu N, Mochida S, 
Asano M, Higashida H (2007) CD38 is critical for social behaviour by regulating 
oxytocin secretion. Nature 446(7131):41-45 
 
Kim UH (2014) Multiple Enzymatic activities of CD38 for Ca2+ signaling. Messenger 
3(1):6-14   
 
Lee HC (2012) The Cyclic ADP-ribose/NAADP/CD38-signaling pathway: Past and 
Present. Messenger 1(1):16-33  
 
Lipton JO, Sahin M (2014) The neurology of mTOR. Neuron 84(2):275-291  
 
Missale C, Nash SR, Robinson SW, Jaber M, Caron MG (1998) Dopamine receptors: 
from structure to function. Physiol Rev 78(1):189-225  
 
 21 
Nagatsu T (2007) The catecholamine system in health and disease -Relation to tyrosine 
3-monooxygenase and other catecholamine-synthesizing enzymes. Proc Jpn Acad Ser B 
Phys Biol Sci 82(10):388-415  
 
Nagatsu T, Nagatsu I(2016) Tyrosine hydroxylase (TH), its cofactor tetrahydrobiopterin 
(BH4), other catecholamine-related enzymes, and their human genes in relation to the 
drug and gene therapies of Parkinson's disease (PD): historical overview and future 
prospects. J Neural Transm (Vienna). 2016 Aug 4. 
 
Nagatsu T, Nakano T, Kato T, Higashida H (1981) Expression of A and B types of 
monoamine oxidase in neuroblastoma hybrid cells. Neurochem Int 3(2):137-142  
 
Nakano T, Nagatsu T, Higashida H (1985) Expression of A and B types of monoamine 
oxidase in differentiated neuroblastoma hybrid cells. J Neurochem 44(3):755-758. 
 
Nakano T, Saito S, Higashida H, Kojima K, Nagatsu T (1986) Assignment of A and B 
types of monoamine oxidase in NCB20 hybrid cells to those of the parental cells by 
peptide mapping. J Neurochem 46(3):686-694  
 
Noguchi N, Takasawa S, Nata K, Tohgo A, Kato I, Ikehata F, Yonekura H, Okamoto H 
(1997) Cyclic ADP-ribose binds to FK506-binding protein 12.6 to release Ca2+ from 
islet microsomes. J Biol Chem 272(6):3133-3136  
 
Okamoto H, Takasawa S, Sugawara A (2014) The CD38-Cyclic ADP-Ribose System in 
Mammals: Historical Background, Pathophysiology and Perspective. Messenger 
3(1):27-34  
 
Roohi A, Hojjat-Farsangi M (2016) Recent advances in targeting mTOR signaling 
pathway using small molecule inhibitors. J Drug Target Oct 3:1-13  
 
Salmina AB, Lopatina O, Ekimova MV, Mikhutkina SV, Higashida H (2010) 
CD38/cyclic ADP-ribose system: a new player for oxytocin secretion and regulation of 
social behaviour. J Neuroendocrinol 22(5):380-392  
 
 22 
Seeman P, Van Tol HH. (1994) Dopamine receptor pharmacology. Trends Pharmacol 
Sci. 15(7):264-270  
 
Santini E, Heiman M, Greengard P, Valjent E, Fisone G (2009) Inhibition of mTOR 
signaling in Parkinson's disease prevents L-DOPA-induced dyskinesia. Sci Signal 
2(80):ra36  
 
Sukhbaatar N, Hengstschläger M, Weichhart T (2010) mTOR-mediated regulation of 
dendritic cell differentiation and function. Trends Immunol pii: S1471-4906(16)30099-0  
 
Sutton LP, Caron MG. (2015) Essential role of D1R in the regulation of mTOR 
complex1 signaling induced by cocaine. Neuropharmacology 99:610-619. doi: 
10.1016/j.neuropharm.2015.08.024. 
 
Suzuki O, Hattori H, Sawada M, Nagatsu T, Miki N, Higashida H (1983) Serotonin in 
neuroblastoma x glioma NG108-15 hybrid cells. Neurochem Int 5(5):599-601  
 
Thomson AW, Turnquist HR, Raimondi G (2009) Immunoregulatory functions of 
mTOR inhibition. Nat Rev Immunol 9(5):324-337  
 
Tramutola A, Lanzillotta C, Di Domenico F. (2016) Targeting mTOR to reduce 
Alzheimer-related cognitive decline: from current hits to future therapies. Expert Rev 
Neurother Oct 2. 
 
Volkow ND, Morales M (2015) The brain on drugs: from reward to addiction. 
Cell 162(4):712-725  
 
Wullschleger S, Loewith R, Hall MN (2006) TOR signaling in growth and metabolism.  
Cell 124 (3):471-484  
 
Yano K, Higashida H, Inoue R, Nozawa Y (1984) Bradykinin-induced rapid breakdown 
of phosphatidylinositol 4,5-bisphosphate in neuroblastoma X glioma hybrid NG108-15 
cells. J Biol Chem 259(16):10201-10207  
 
 23 
Zhang JS, Jin D, Higashida H (2005) Acetylcholine stimulates cyclic ADP-ribose 
formation via M1 muscarinic receptors in rat superior cervical ganglion. Biochem 
Biophys Res Commun 335(3):920-924  
 
Zhang X, Tallini YN, Chen Z, Gan L, Wei B, Doran R, Miao L, Xin HB, Kotlikoff MI, 
Ji G (2009) Dissociation of FKBP12.6 from ryanodine receptor type 2 is regulated by 
cyclic ADP-ribose but not beta-adrenergic stimulation in mouse cardiomyocytes. 




Table 1 Effects of cADPR and rapamycin on S6 kinase phosphorylation in the male 
mouse striatum  
Inhibitors Ratio  %  n P 
None  1.28 ± 0.16 (100)  22 
cADPR  0.76 ± 0.04 (59)  18 < 0.05 
Rapamycin 0.56 ± 0.03 (44)  16 < 0.02 
  
After adaptive preincubation for 60 minutes, striatal slices were incubated with or 
without 100 µM cADPR or 100 µM rapamycin for 5 minutes at 35°C. Changes in S6K 
phosphorylation were quantified after a 5-minute incubation (P-S6K/S6K). Data were 
alculated as the percentage change between 0 and 5 minutes (P-S6K/S6K at 5 minutes 
divided by P-S6K/S6K at 0 minutes). Data are presented as the mean ± SEM of 16–22 
preparations. P, relative to control (two-tailed t test). 
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Table 2. Effects of cADPR on S6 kinase phosphorylation in striata isolated from 
MPTP-treated mice 
 
  Ratio (%)   Ratio (%) 
 Mice  Control    MPTP-treated  
None  1.19 ± 0.13 (100) 1.22 ± 3.4 (100) 
+cADPR 0.80 ± 0.09 (67)* 0.93 ± 0.16 (76)n.s.   
 
After adaptive preincubation for 60 minutes, striatal slices were incubated with or 
without 100 µM cADPR for 5 minutes at 35°C. Changes in S6K phosphorylation were 
quantified after a 5-minute incubation (P-S6K/S6K). Data were calculated as the 
percentage change between 0 and 5 minutes (P-S6K/S6K at 5 minutes divided by 
P-S6K/S6K at 0 minutes). Data are presented as the mean ± SEM.  N = 14 (none) and 





Figure 1. Developmental regulation of basal ADP-ribosyl cyclase activity in striatal 
membranes of mice at various ages. Developmental time course of cyclase activity. 
ADP-ribosyl cyclase was measured fluorometrically as the rate of cGDPR formation. Data 
are presented as the mean ± SEM of 4–6 determinations. *, Significantly different from 
postnatal day 1 (P < 0.001, Bonferroni’s post-hoc test). One unit represents 20.5 
pmol/min/mg protein. 
 
Figure 2. Relationship between ADP-ribosyl cyclase activity and various 
concentrations of DA or two DA agonists with or without GTP in the reaction 
mixture. 
Cell membranes were isolated from the striata of 3-day-old neonatal mice. (A) 
Relationship between cGDPR formation and DA concentration with (closed circles) or 
without 10 nM GTP (open circles). (B) Concentration dependency of SKF (squares) and 
BC (circles) on cGDPR formation. n = 10. Two-way (A) or one-way (B) ANOVA with 
post-hoc Bonferroni’s test was evaluated. * and **, Significantly different from control 
(P < 0.05 and P < 0.001, respectively, one-way ANOVA).  
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Figure 3. Representative results of Western blotting analysis of mouse CD38. Cell 
lysates from the striata of mice at the indicated ages were separated by 8% SDS-PAGE. 
The blot was probed with an anti-murine CD38 antibody. 
 
Figure 4. FKBP12.6 mRNA expression. FKBP12.6 mRNA expression was analyzed 
by RT-PCR in four brain regions and the pituitary in 9-week-old male mice using 
β-actin mRNA as an internal control. Quantitative data are shown as the mean ± SEM (n 
= 5 independent experiments) of FKBP12.6/actin. One-way ANOVA followed by 
Bonferroni’s post hoc test: F4,12 = 30.99, *P < 0.002, **P < 0.001. Modified from 
Figure 6 of our previous report [9]. 
 
Figure 5. Effects of cADPR on S6 kinase phosphorylation in the striata of 
9-week-old male mice. After adaptive preincubation for 60 minutes, striatal slices were 
incubated with or without 100 µM cADPR alone or together with 100 µM 
8-bromo-cADPR (8-Br-cADPR) for 5 minutes at 35°C. Representative Western blots of 
phosphorylated S6 kinase (Thr389; P-S6K) and total S6 kinase (S6K) in the absence (A) 
or presence (B) of 100 nM DA. Changes in S6K phosphorylation were quantified after a 
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5-minute incubation (P-S6K/S6K). Data were calculated as the percentage change 
between 0 and 5 minutes (P-S6K/S6K at 5 minutes divided by P-S6K/S6K at 0 minutes). 
Data are presented as the mean ± SEM of 16 controls (without cADPR and 
8-Br-cADPR), 22 preparations treated with cADPR, and 8 samples treated with 
cADPR+8-Br-cADPR. One-way ANOVA with Bonferroni’s post-hoc test was evaluated 
for significance (see text). *P < 0.03 for the comparison of control and 8-Br-cADPR 
(two-tailed t test). Modified from Figure 6 of our previous report [9]. 
 
Figure 6. Schematic of the proposed role of endogenous cADPR and exogenous 
rapamycin in the striatum. cADPR or rapamycin with FKBP inhibits the mTORC1 
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